Payment overview · 2025
General Payments
$407.60
20 reported records · 10 companies
Healthcare provider profile · identity verified
Sarah Mcbride Bautista
Allopathic & Osteopathic Physicians|Internal Medicine · METAIRIE, LA · NPI 1588026447
Verified facts
What the public records show
CMS Open Payments records show Sarah Mcbride Bautista received $407.60 in general payments during 2025 across 20 reported records.
Dexcom, Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $103.64 | 25.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.17 | 15.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.28 | 11.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.93 | 10.3% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $41.30 | 10.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.86 | 9.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.15 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.51 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.11 | 4.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.65 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $407.60 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $103.64 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $63.17 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $48.28 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| AMS 800 Artificial Urinary Sphincter Normalized: ams 800 artificial urinary sphincter |
Device | Boston Scientific Corporation | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
109 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 140 |
| Gabapentin | Gabapentin | 423 | 88 |
| Losartan Potassium | Losartan Potassium | 333 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 78 |
| Lisinopril | Lisinopril | 244 | 65 |
| Metformin Hcl | Metformin Hcl | 224 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 57 |
| Omeprazole | Omeprazole | 176 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 43 |
| Trazodone Hcl | Trazodone Hcl | 166 | 31 |
| Eliquis | Apixaban | 151 | 29 |
| Januvia | Sitagliptin Phosphate | 151 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 30 |
| Ozempic | Semaglutide | 122 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 33 |
| Mounjaro | Tirzepatide | 109 | 20 |
| Carvedilol | Carvedilol | 101 | 32 |
| Pregabalin | Pregabalin | 79 | 25 |
| Tramadol Hcl | Tramadol Hcl | 79 | 25 |
| Montelukast Sodium | Montelukast Sodium | 73 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 24 |
| Jardiance | Empagliflozin | 72 | 15 |
| Famotidine | Famotidine | 71 | 23 |
| Furosemide | Furosemide | 69 | 26 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Alendronate Sodium | Alendronate Sodium | 66 | 17 |
| Allopurinol | Allopurinol | 65 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Metformin Hcl Er | Metformin Hcl | 58 | 21 |
| Irbesartan | Irbesartan | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 11 |
| Azelastine Hcl | Azelastine Hcl | 47 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 14 |
| Simvastatin | Simvastatin | 47 | 15 |
| Chlorthalidone | Chlorthalidone | 44 | 14 |
| Nifedipine Er | Nifedipine | 44 | 11 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 16 |
| Glipizide | Glipizide | 40 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 15 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 15 |
| Mupirocin | Mupirocin | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Jinteli | Norethindrone Ac/Eth Estradiol | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.60 · 20 records | Dexcom, Inc. | ABRYSVO, AMS 800 Artificial Urinary Sphincter, COMIRNATY, CONTRAVE, Dexcom G6 Transmitter, ELAHERE, FREESTYLE LIBRE, KEYTRUDA, MOUNJARO, ONZETRA XSAIL, PREVNAR 20, The Cologuard Plus Collection Kit, ZEPBOUND, ZTLido | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error